Development of a Nanobody-Based Lateral Flow Immunoassay for Detection of Human Norovirus

• DOI: 10.1128/msphere.00219-16
• Publication Date: 2016-10-13T01:59:23Z
• Authors: Sylvie Y. Doerfli...; Julia Tabatabai; Paul Schnitzler; Carlo Farah; Steffen Rameil; Peter Sander; Anna Koromyslova; Grant S. Hansman
• Keywords: 0303 health sciences; 03 medical and health sciences; Nanobody; norovirus; lateral flow assay; Observation; Microbiology; QR1-502; 3. Good health

We previously identified a Nanobody (termed Nano-85) that bound to a highly conserved region on the norovirus capsid. In this study, the Nanobody was biotinylated and gold conjugated for a lateral flow immunoassay (termed Nano-IC). We showed that the Nano-IC assay was capable of detecting at least four antigenically distinct GII genotypes, including the newly emerging GII.17. In the clinical setting, the Nano-IC assay had sensitivities equivalent to other commercially available lateral flow systems. The Nano-IC method was capable of producing results in ~5 min, which makes this method useful in settings that require rapid diagnosis, such as cruise ship outbreaks and elder care facilities. The Nano-IC assay has several advantages over antibody-based IC methods: for example, Nanobodies can be readily produced in large quantities, they are generally more stable than conventional antibodies, and the Nanobody binding sites can be easily obtained by X-ray crystallography.